CN101235027B - 一种椒苯酮胺晶体及其制备方法和药物用途 - Google Patents
一种椒苯酮胺晶体及其制备方法和药物用途 Download PDFInfo
- Publication number
- CN101235027B CN101235027B CN2007100032341A CN200710003234A CN101235027B CN 101235027 B CN101235027 B CN 101235027B CN 2007100032341 A CN2007100032341 A CN 2007100032341A CN 200710003234 A CN200710003234 A CN 200710003234A CN 101235027 B CN101235027 B CN 101235027B
- Authority
- CN
- China
- Prior art keywords
- xanthiphenyl
- ketamine
- crystal
- solution
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 108
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 238000003860 storage Methods 0.000 claims abstract description 4
- 229960003299 ketamine Drugs 0.000 claims description 99
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 97
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 43
- 238000001035 drying Methods 0.000 claims description 32
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 30
- 238000001914 filtration Methods 0.000 claims description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000012044 organic layer Substances 0.000 claims description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 14
- 238000002425 crystallisation Methods 0.000 claims description 14
- 230000008025 crystallization Effects 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 238000001816 cooling Methods 0.000 claims description 12
- 239000005457 ice water Substances 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000010410 layer Substances 0.000 claims description 7
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 5
- 239000012047 saturated solution Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- -1 3, 4-methylenedioxy phenylethyl Chemical group 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 description 39
- 239000002253 acid Substances 0.000 description 22
- 206010013786 Dry skin Diseases 0.000 description 20
- 230000002107 myocardial effect Effects 0.000 description 17
- 238000012856 packing Methods 0.000 description 14
- 238000005303 weighing Methods 0.000 description 14
- 206010019280 Heart failures Diseases 0.000 description 13
- 238000004108 freeze drying Methods 0.000 description 13
- 229910001220 stainless steel Inorganic materials 0.000 description 13
- 239000010935 stainless steel Substances 0.000 description 13
- 230000001954 sterilising effect Effects 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 239000007864 aqueous solution Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000001186 cumulative effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 238000000859 sublimation Methods 0.000 description 10
- 230000008022 sublimation Effects 0.000 description 10
- 206010063837 Reperfusion injury Diseases 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 102000004420 Creatine Kinase Human genes 0.000 description 8
- 108010042126 Creatine kinase Proteins 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229960000935 dehydrated alcohol Drugs 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008719 thickening Effects 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000003680 myocardial damage Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 235000015961 tonic Nutrition 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 description 3
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 229940071870 hydroiodic acid Drugs 0.000 description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 229940122434 Calcium sensitizer Drugs 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 description 2
- 229960000692 levosimendan Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- JEJGJJSMKOHPTP-XBXARRHUSA-N (E)-5-[2-(1,3-benzodioxol-5-yl)ethyl-methylamino]-1-(4-hydroxyphenyl)pent-1-en-3-one Chemical compound C=1C=C2OCOC2=CC=1CCN(C)CCC(=O)\C=C\C1=CC=C(O)C=C1 JEJGJJSMKOHPTP-XBXARRHUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102220473066 Chemerin-like receptor 2_H20A_mutation Human genes 0.000 description 1
- 102000002585 Contractile Proteins Human genes 0.000 description 1
- 108010068426 Contractile Proteins Proteins 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019332 Heat exhaustion Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 102220475870 Keratin, type I cytoskeletal 10_H13A_mutation Human genes 0.000 description 1
- 102220479923 Leucine-rich repeat-containing protein 26_H11A_mutation Human genes 0.000 description 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102220492046 Phospholipid scramblase 1_H12A_mutation Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102220577960 RPA-interacting protein_H21A_mutation Human genes 0.000 description 1
- 102220608658 Secreted phosphoprotein 24_H10A_mutation Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000003540 papillary muscle Anatomy 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 229920003366 poly(p-phenylene terephthalamide) Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000000547 structure data Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
x | y | z | Biso | |
O1 | .8027(4) | .2305(4) | .7081(1) | 4.4(2) |
O2 | .4146(4) | .3102(5) | .3723(1) | 5.0(2) |
O3 | 1.3846(5) | .0992(7) | .0440(2) | 8.5(3) |
O4 | 1.2222(6) | .1515(10) | -.0059(3) | 7.6(4) |
N1 | .6966(4) | .0319(5) | .2444(2) | 3.5(2) |
C1 | .7507(5) | .2119(6) | .6533(2) | 3.1(2) |
C2 | .6661(5) | .3231(6) | .6342(2) | 3.4(3) |
x | y | z | Biso | |
C3 | .6196(5) | .3018(6) | .5775(2) | 3.2(2) |
C4 | .6551(4) | .1685(6) | .5389(2) | 2.6(2) |
C5 | .7268(5) | .5077(6) | .5603(2) | 3.0(2) |
C6 | .7850(5) | .0775(7) | .6168(2) | 3.5(3) |
C7 | .6115(5) | .1446(6) | .4771(2) | 2.9(2) |
C8 | .5244(5) | .2316(6) | .4536(2) | 3.1(2) |
C9 | .4892(5) | .2143(7) | .3902(3) | 3.4(2) |
C10 | .5439(5) | .0824(6) | .3443(2) | 3.3(3) |
C11 | .6506(5) | .1498(7) | .2944(2) | 3.7(3) |
C12 | .8241(5) | .0801(7) | .2098(3) | 4.2(3) |
C13 | .8884(7) | -.0544(8) | 01677(3) | 6.0(4) |
C14 | 1.0236(6) | -.0116(7) | .1372(2) | 4.3(3) |
C15 | 1.0459(6) | .0600(8) | .0772(3) | 5.3(3) |
C16 | 1.1701(6) | .0913(8) | .0503(3) | 5.6(3) |
C17 | 1.2701(6) | .0555(8) | .0822(3) | 5.5(3) |
C18 | 1.2502(6) | -.0096(9) | .1420(3) | 5.9(3) |
C19 | 1.1245(6) | -.0429(8) | .1694(3) | 5.2(3) |
C20 | 1.3411(10) | .1283(15) | -.0160(4) | 9.4(6) |
C21 | .6028(6) | .0124(9) | .2003(3) | 5.5(3) |
HO1 | .766 | .341 | .732 | 5.2 |
x | y | z | Biso | |
H2 | .637 | .427 | .664 | 4.5 |
H3 | .554 | .388 | .562 | 4.1 |
H5 | .761 | -.049 | .532 | 3.9 |
H6 | .852 | -.101 | .632 | 4.4 |
H7 | .652 | .043 | .447 | 3.8 |
H8 | .475 | .324 | .485 | 4.3 |
H10A | .582 | -.012 | .372 | 4.2 |
H10B | .468 | .031 | .322 | 4.2 |
H11A | .729 | .188 | .317 | 4.5 |
H11B | .613 | .252 | .272 | 4.5 |
H12A | .814 | .182 | .179 | 5.1 |
H12B | .887 | .117 | .243 | 5.1 |
H13A | .832 | -.084 | .131 | 7.1 |
H13B | .891 | -.160 | .198 | 7.1 |
H15 | .966 | .092 | .052 | 6.3 |
H18 | 1.332 | -.034 | .168 | 6.2 |
H19 | 1.107 | -.099 | .217 | 6.0 |
H20A | 1.407 | .229 | -.041 | 10.6 |
H20B | 1.378 | .025 | -.050 | 10.6 |
H21A | .589 | .123 | .175 | 6.4 |
x | y | z | Biso | |
H21B | .509 | -.023 | .226 | 6.4 |
H21C | .640 | -.078 | .167 | 6.4 |
O(1)-C(1) | 1.369(6) | C(10)-C(11) | 1.527(8) |
O(1)-HO(1) | 1.080(4) | C(10)-H(10A) | 1.102(8) |
O(2)-C(9) | 1.226(7) | C(10)-H(10B) | 1.089(8) |
O(3)-C(17) | 1.394(8) | C(11)-H(11A) | 1.076(8) |
O(3)-C(20) | 1.431(11) | C(11)-H(11B) | 1.093(9) |
O(4)-C(16) | 1.381(8) | C(12)-C(13) | 1.534(9) |
O(4)-C(20) | 1.420(11) | C(12)-H(12A) | 1.097(9) |
N(1)-C(11) | 1.473(7) | C(12)-H(12B) | 1.092(8) |
N(1)-C(12) | 1.482(7) | C(13)-C(14) | 1.514(9) |
N(1)-C(21) | 1.481(7) | C(13)-H(13A) | 1.080(9) |
C(1)-C(2) | 1.401(7) | C(13)-H(13B) | 1.104(10) |
C(1)-C(6) | 1.386(8) | C(14)-C(15) | 1.393(8) |
C(2)-C(3) | 1.385(7) | C(14)-C(19) | 1.387(9) |
C(2)-H(2) | 1.099(9) | C(15)-C(16) | 1.358(9) |
C(3)-C(4) | 1.406(7) | C(15)-H(15) | 1.101(8) |
C(3)-H(3) | 1.090(8) | C(16)-C(17) | 1.384(10) |
C(4)-C(5) | 1.394(7) | C(17)-C(18) | 1.349(9) |
O(1)-C(1) | 1.369(6) | C(10)-C(11) | 1.527(8) |
C(4)-C(7) | 1.471(7) | C(18)-C(19) | 1.389(10) |
C(5)-C(6) | 1.385(8) | C(18)-H(18) | 1.120(9) |
C(5)-H(5) | 1.091(9) | C(19)-H(19) | 1.100(9) |
C(6)-H(6) | 1.101(8) | C(20)-H(20A) | 1.107(11) |
C(7)-C(8) | 1.331(7) | C(20)-H(20B) | 1.125(12) |
C(7)-H(7) | 1.109(8) | C(21)-H(21A) | 1.091(10) |
C(8)-C(9) | 1.465(7) | C(21)-H(21B) | 1.092(9) |
C(8)-H(8) | 1.101(8) | C(21)-H(21C) | 1.076(9) |
C(9)-C(10) | 1.523(8) |
C(1)-O(1)-HO(1) | 109.5(4) | H(11A)-C(11)-H(11B) | 108.8(7) |
C(17)-O(3)-C(20) | 104.4(5) | N(1)-C(12)-C(13) | 111.2(5) |
C(16)-O(4)-C(20) | 104.8(6) | N(1)-C(12)-H(12A) | 110.7(6) |
C(11)-N(1)-C(12) | 109.5(4) | N(1)-C(12)-H(12B) | 110.9(6) |
C(11)-N(1)-C(21) | 110.3(4) | C(13)-C(12)-H(12A) | 107.7(6) |
C(12)-N(1)-C(21) | 111.6(4) | C(13)-C(12)-H(12B) | 108.9(6) |
O(1)-C(1)-C(2) | 121.4(5) | H(12A)-C(12)-H(12B) | 107.3(7) |
O(1)-C(1)-C(6) | 118.3(5) | C(12)-C(13)-C(14) | 111.6(5) |
C(2)-C(1)-C(6) | 120.3(5) | C(12)-C(13)-H(13A) | 110.0(7) |
C(1)-C(2)-C(3) | 120.0(5) | C(12)-C(13)-H(13B) | 108.2(6) |
C(1)-O(1)-HO(1) | 109.5(4) | H(11A)-C(11)-H(11B) | 108.8(7) |
C(1)-C(2)-H(2) | 120.1(6) | C(14)-C(13)-H(13A) | 110.0(6) |
C(3)-C(2)-H(2) | 119.9(6) | C(14)-C(13)-H(13B) | 109.1(7) |
C(2)-C(3)-C(4) | 120.7(5) | H(13A)-C(13)-H(13B) | 107.7(8) |
C(2)-C(3)-H(3) | 120.2(6) | C(13)-C(14)-C(15) | 120.3(6) |
C(4)-C(3)-H(3) | 119.1(6) | C(13)-C(14)-C(19) | 120.1(5) |
C(3)-C(4)-C(5) | 117.6(5) | C(15)-C(14)-C(19) | 119.6(6) |
C(3)-C(4)-C(7) | 122.1(5) | C(14)-C(15)-C(16) | 117.6(6) |
C(5)-C(4)-C(7) | 120.3(5) | C(14)-C(15)-H(15) | 120.6(7) |
C(4)-C(5)-C(6) | 122.6(5) | C(16)-C(15)-H(15) | 121.8(7) |
C(4)-C(5)-H(5) | 118.1(6) | O(4)-C(16)-C(15) | 128.1(6) |
C(6)-C(5)-H(5) | 119.3(6) | O(4)-C(16)-C(17) | 109.7(6) |
C(1)-C(6)-C(5) | 118.7(5) | C(15)-C(16)-C(17) | 122.2(6) |
C(1)-C(6)-H(6) | 120.6(6) | O(3)-C(17)-C(16) | 108.9(6) |
C(5)-C(6)-H(6) | 120.7(6) | O(3)-C(17)-C(18) | 129.9(6) |
C(4)-C(7)-C(8) | 126.3(5) | C(16)-C(17)-C(18) | 121.2(6) |
C(4)-C(7)-H(7) | 117.3(5) | C(17)-C(18)-C(19) | 117.6(6) |
C(8)-C(7)-H(7) | 116.4(6) | C(17)-C(18)-H(18) | 120.9(7) |
C(7)-C(8)-C(9) | 125.4(5) | C(19)-C(18)-H(18) | 121.5(7) |
C(7)-C(8)-H(8) | 116.8(6) | C(14)-C(19)-C(18) | 121.7(5) |
C(9)-C(8)-H(8) | 117.7(6) | C(14)-C(19)-H(19) | 119.7(7) |
C(1)-O(1)-HO(1) | 109.5(4) | H(11A)-C(11)-H(11B) | 108.8(7) |
O(2)-C(9)-C(8) | 119.2(5) | C(18)-C(19)-H(19) | 118.6(7) |
O(2)-C(9)-C(10) | 118.9(5) | O(3)-C(20)-O(4) | 107.6(6) |
C(8)-C(9)-C(10) | 121.9(5) | O(3)-C(20)-H(20A) | 109.9(8) |
C(9)-C(10)-C(11) | 109.5(4) | O(3)-C(20)-H(20B) | 109.7(9) |
C(9)-C(10)-H(10A) | 109.5(5) | O(4)-C(20)-H(20A) | 113.1(10) |
C(9)-C(10)-H(10B) | 109.7(6) | O(4)-C(20)-H(20B) | 112.1(8) |
C(110-C(10)-H(10A) | 109.8(6) | H(20A)-C(20)-H(20B) | 104.4(8) |
C(11)-C(10)-H(10B) | 111.1(6) | N(1)-C(21)-H(21A) | 111.8(6) |
H(10A)-C(10)-H(10B) | 107.2(7) | N(1)-C(21)-H(21B) | 111.6(6) |
N(1)-C(11)-C(10) | 111.6(4) | N(1)-C(21)-H(21C) | 106.1(6) |
N(1)-C(11)-H(11A) | 110.0(6) | H(21A)-C(21)-H(21B) | 107.8(7) |
N(1)-C(11)-H(11B) | 109.0(5) | H(21A)-C(21)-H(21C) | 109.9(7) |
C(10)-C(11)-H(11A) | 109.5(6) | H(21B)-C(21)-H(21C) | 109.8(8) |
C(10)-C(11)-H(11B) | 107.9(6) |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100032341A CN101235027B (zh) | 2007-01-31 | 2007-01-31 | 一种椒苯酮胺晶体及其制备方法和药物用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100032341A CN101235027B (zh) | 2007-01-31 | 2007-01-31 | 一种椒苯酮胺晶体及其制备方法和药物用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101235027A CN101235027A (zh) | 2008-08-06 |
CN101235027B true CN101235027B (zh) | 2010-11-10 |
Family
ID=39918964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100032341A Expired - Fee Related CN101235027B (zh) | 2007-01-31 | 2007-01-31 | 一种椒苯酮胺晶体及其制备方法和药物用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101235027B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028681B (zh) * | 2009-09-24 | 2012-05-30 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐在制备预防/治疗脑病的药物中的用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1395923A (zh) * | 2002-07-24 | 2003-02-12 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐用作制备治疗心血管疾病药物的应用 |
CN1396162A (zh) * | 2002-07-24 | 2003-02-12 | 广州市众为生物技术有限公司 | 椒苯酮胺、椒苯酮胺盐及其制备方法 |
-
2007
- 2007-01-31 CN CN2007100032341A patent/CN101235027B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1395923A (zh) * | 2002-07-24 | 2003-02-12 | 广州市众为生物技术有限公司 | 椒苯酮胺或其盐用作制备治疗心血管疾病药物的应用 |
CN1396162A (zh) * | 2002-07-24 | 2003-02-12 | 广州市众为生物技术有限公司 | 椒苯酮胺、椒苯酮胺盐及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101235027A (zh) | 2008-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2762522B2 (ja) | 血管新生阻害剤 | |
DE60004793T2 (de) | Echinocandin-kohlenhydrate-komplexe | |
CN108473474A (zh) | 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法 | |
CN100584835C (zh) | 桂哌齐特的药用盐及其制备方法 | |
CN103360456B (zh) | 三萜类化合物及制备和应用 | |
CN101235027B (zh) | 一种椒苯酮胺晶体及其制备方法和药物用途 | |
CN101289438A (zh) | 3-(3′-羟基)-丁基苯酞酯及其制法和用途 | |
AU2015268575B2 (en) | Derivative of butylphthalide and preparation method and use thereof | |
CN110054606A (zh) | 一种二氢杨梅素-盐酸黄连素药物共晶及制备方法 | |
CN103183722B (zh) | 一种乙二醛酶i抑制剂及其制备方法和医药用途 | |
CN113185447B (zh) | 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途 | |
JP7026264B2 (ja) | ポサコナゾールホスフェートモノコリン塩、その調製方法及び用途 | |
CN101708179B (zh) | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 | |
CN106146612B (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
CN103012358A (zh) | 自牛樟芝萃取的化合物、含该化合物的医药组合物及该化合物的用途 | |
CN102100695B (zh) | 一种安全性高的桂哌齐特药用组合物及其制备方法和其应用 | |
WO2005037841A1 (fr) | Concentricolide et ses derives, preparation associee et compositions pharmaceutiques contenant celui-ci et utilisations correspondantes | |
CN105037490B (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
CN104230864A (zh) | 新的羟基红花黄色素a二价药用盐及其制备方法和用途 | |
CN115073368B (zh) | 一种米力农-5-磺基水杨酸晶型 | |
CN105646493B (zh) | 一种用于预防和治疗器官损伤的化合物及其制备方法和用途 | |
CN100525759C (zh) | 一种用于治疗缺血性脑血管疾病的中成药 | |
CN108929320A (zh) | 3r-吲哚甲基-6r-恶唑烷酮修饰的哌嗪-2,5-二酮,其合成,活性和应用 | |
CN102503954B (zh) | 咪唑衍生物、其制备方法和用途 | |
WO2019114501A1 (zh) | α-楝子素衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHONGWEI BIOTECHNOLOGY CO LTD, GUANGZHOU CITY Effective date: 20140121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510633 GUANGZHOU, GUANGDONG PROVINCE TO: 214000 WUXI, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140121 Address after: 214000 No. 12 Changjiang Road, New District, Jiangsu, Wuxi Patentee after: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL Co.,Ltd. Address before: 510633 E413 room, international business incubator, Daguan Road, Guangzhou Science City, Guangdong Patentee before: GUANGZHOU MUNICIPAL ZHONGWEI BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 214028 Changjiang South Road, new Wu District, Wuxi, Jiangsu Province, No. 12 Patentee after: Wuxi Jiyu Shanhe Pharmaceutical Co.,Ltd. Address before: No.12, Changjiang Road, New District, Wuxi, Jiangsu Province Patentee before: WUXI JIMIN KEXIN SHANHE PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211130 Address after: 330052 No. 1, hEPO Road, Xiaolan economic and Technological Development Zone, Nanchang City, Jiangxi Province Patentee after: Jiangxi Guoneng Pharmaceutical Technology Co.,Ltd. Address before: No.12, South Changjiang Road, Xinwu District, Wuxi City, Jiangsu Province Patentee before: Wuxi Jiyu Shanhe Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101110 |